Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
Shockwave Medical, a Johnson & Johnson MedTech company, has officially launched its Shockwave E8 Peripheral IVL Catheter in the United States. Shockwave’s E8 catheter was designed specifically to treat patients with calcified femoropopliteal and below-the-knee (BTK) peripheral artery disease (PAD), including those diagnosed with complex chronic limb-threatening ischemia (CLTI).

Shockwave Medical launches new FDA-approved IVL catheter for PAD, CLTI

The new device, already cleared by the FDA, was designed to treat femoropopliteal and below-the-knee PAD. 

SpectraWAVE, a Massachusetts-based imaging company focused on treatments for patients with coronary artery disease (CAD), has closed a $50 million funding round. Johnson & Johnson Innovation led the round, and other participants included S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture and Heartwork Capital.

SpectraWAVE raises $50M for FDA-cleared intravascular imaging technology

The funds, including a significant investment from Johnson & Johnson, are expected to go toward expanding access to the company's HyperVue Imaging System and exploring new features.

A demonstration of SenitAR's augmented reality (AR) technology for electrophysiology lab procedures during the Heart Rhythm Society 2024 meeting. This is one of at least six FDA-cleared clinical AR and virtual reality applications that aimed at enhancing cardiology workflow and patient outcomes. Photo by Dave Fornell

A glimpse into the future: FDA has cleared multiple AR, VR tools for cardiology

Heart teams already have access to several augmented reality and virtual reality offerings, and many more are on the way.

Implantable Barostim device improves long-term heart failure symptoms

The FDA-approved device helps regulate the heart, kidneys and vascular system by targeting sensors in a patient's carotid artery. 

Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

TRILUMINATE update: TEER with Abbott’s TriClip device still safe, effective after 3 years

Treatment with TriClip has been consistently associated with minimal adverse events and significant improvements in quality of life. This latest update represents data from nearly 100 patients three years after implantation.  

cross market hospital mergers

Abiomed, Biosense Webster, Cerenovus now all known as Johnson & Johnson MedTech

These companies were already part of the Johnson & Johnson family, but they had still retained their previous brand names. Now, each one is officially going by Johnson & Johnson MedTech. 

Map of Congressional districts and the rate of amputations based on medicare data showing Mississippi delta region with the highest number of amputation procedures per year. Dr. Fakorede located his practice there to try and combat extremely the high PAD and CLI rates.

PAD is a public health crisis say cardiovascular societies

September is peripheral artery disease (PAD) awareness month, and medical societies are using it to promote awareness for patients and referring physicians to act against the debilitating disease.
 

Thumbnail

‘An excellent outcome’: TAVR safe and effective for patients in their nineties

Bleeding and vascular complications were more common, but one-year outcomes confirmed patients in their nineties should still be considered for TAVR.

Displaying 65 - 72 of 973
Design by Adaptive Theme